These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8968650)

  • 101. Subjective response to neuroleptics and the quality of life: implications for treatment outcome.
    Awad AG; Hogan TP
    Acta Psychiatr Scand Suppl; 1994; 380():27-32. PubMed ID: 7914044
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Important issues in the drug treatment of schizophrenia.
    Davis JM; Schaffer CB; Killian GA; Kinard C; Chan C
    Schizophr Bull; 1980; 6(1):70-87. PubMed ID: 6102795
    [TBL] [Abstract][Full Text] [Related]  

  • 103. [Efficacy and tolerance of antipsychotic agents: what are the current issues?].
    Canceil O
    Encephale; 2006 Oct; 32(5 Pt 4):S927-8. PubMed ID: 17119510
    [No Abstract]   [Full Text] [Related]  

  • 104. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients.
    McEvoy JP; Howe AC; Hogarty GE
    J Nerv Ment Dis; 1984 Jul; 172(7):412-6. PubMed ID: 6144721
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Quality-of-life assessment in schizophrenia: the unfulfilled promise.
    Awad AG
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):491-3. PubMed ID: 21958091
    [No Abstract]   [Full Text] [Related]  

  • 106. Chronic schizophrenia.
    Morgan R
    Br J Hosp Med; 1985 Oct; 34(4):202-5. PubMed ID: 2868767
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Thoughts About Schizophrenia 66 Years After Chlorpromazine.
    Meyer RE
    J Clin Psychopharmacol; 2020; 40(5):436-438. PubMed ID: 32833876
    [No Abstract]   [Full Text] [Related]  

  • 108. A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information.
    Goyal N; Gomeni R
    Clin Pharmacol Ther; 2012 Feb; 91(2):215-9. PubMed ID: 22089266
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia.
    Wyatt RJ
    Schizophr Res; 1991 Oct; 5(3):201-2. PubMed ID: 1684719
    [No Abstract]   [Full Text] [Related]  

  • 110. The importance of non-biological factors in influencing the outcome of clinical trials.
    Gaebel W
    Br J Psychiatry Suppl; 1993 Dec; (22):45-50. PubMed ID: 8110443
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Violent behavior among schizophrenic patients.
    Graham LA; Thienhaus OJ; Somoya E
    Am J Psychiatry; 1990 Oct; 147(10):1383-5. PubMed ID: 1975992
    [No Abstract]   [Full Text] [Related]  

  • 112. The use of videotaped assessment in relation to a study of enhanced management in treatment-resistant schizophrenia.
    Owens DG; Finlayson A; Mercer G; Johnstone EC
    J Psychopharmacol; 1997; 11(4):357-60. PubMed ID: 9443525
    [TBL] [Abstract][Full Text] [Related]  

  • 113. [The routine prescription: between references and reality].
    Lachaux B
    Encephale; 2006 Oct; 32(5 Pt 3):S873-4. PubMed ID: 17119491
    [No Abstract]   [Full Text] [Related]  

  • 114. P-chlorophenylalanine trials in schizophrenic patients.
    DeLisi LE; Freed WJ; Gillin JC; Kleinman JE; Bigelow LB; Wyatt RJ
    Biol Psychiatry; 1982 Apr; 17(4):471-7. PubMed ID: 6211196
    [No Abstract]   [Full Text] [Related]  

  • 115. Allopurinol for treatment-resistant schizophrenia and epilepsy: a case report.
    Liang CS; Yang FW; Chiang KT; Ho PS
    Pharmacopsychiatry; 2010 Aug; 43(6):233-4. PubMed ID: 20486042
    [No Abstract]   [Full Text] [Related]  

  • 116. Cysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia.
    Buckley PF; Miller BJ; Pillai A; Kirkpatrick B
    Schizophr Res; 2014 Sep; 158(1-3):268-9. PubMed ID: 25052781
    [No Abstract]   [Full Text] [Related]  

  • 117. Clinical trials during the prodromal stage of schizophrenia.
    Addington J; Addington D
    Am J Psychiatry; 2005 Jul; 162(7):1387. PubMed ID: 15994732
    [No Abstract]   [Full Text] [Related]  

  • 118. Combined alprazolam and neuroleptic drug in treating schizophrenia.
    Bacher NM; Lewis HA; Field PB
    Am J Psychiatry; 1986 Oct; 143(10):1311-3. PubMed ID: 2876649
    [No Abstract]   [Full Text] [Related]  

  • 119. Pfizer educational forum conference-Socratic dialogue: the body and mind: atypical antipsychotics, physical well-being and compliance. September 22nd, 2003 Prague, Czech Republic Municipal House, Square of Republic, 111 21 Prague 1 Czech Republic.
    Shelley P
    Int J Psychiatr Nurs Res; 2004 Jan; 9(2):1043-4. PubMed ID: 14964044
    [No Abstract]   [Full Text] [Related]  

  • 120. Applications of the AMP/AMDP-System to drug trials.
    Mod Probl Pharmacopsychiatry; 1983; 20():204-10. PubMed ID: 6137767
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.